NEWS RELEASE

2021.02.15

TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH

TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH.

 

For detail information, see the TERNS's press release.

https://ir.ternspharma.com/news-releases/news-release-details/terns-announces-fda-clearance-investigational-new-drug-ind